JP2023545071A5 - - Google Patents
Info
- Publication number
- JP2023545071A5 JP2023545071A5 JP2023521443A JP2023521443A JP2023545071A5 JP 2023545071 A5 JP2023545071 A5 JP 2023545071A5 JP 2023521443 A JP2023521443 A JP 2023521443A JP 2023521443 A JP2023521443 A JP 2023521443A JP 2023545071 A5 JP2023545071 A5 JP 2023545071A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- cancer
- polynucleotide according
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089752P | 2020-10-09 | 2020-10-09 | |
| US63/089,752 | 2020-10-09 | ||
| PCT/US2021/053971 WO2022076685A1 (en) | 2020-10-09 | 2021-10-07 | Methods and compositions comprising pd1 chimeric polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023545071A JP2023545071A (ja) | 2023-10-26 |
| JP2023545071A5 true JP2023545071A5 (https=) | 2024-10-03 |
Family
ID=81125513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023521443A Pending JP2023545071A (ja) | 2020-10-09 | 2021-10-07 | Ｐｄ１キメラポリペプチドを含む方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230374104A1 (https=) |
| EP (1) | EP4229079A4 (https=) |
| JP (1) | JP2023545071A (https=) |
| CN (1) | CN116917338A (https=) |
| AU (1) | AU2021358524A1 (https=) |
| CA (1) | CA3198363A1 (https=) |
| WO (1) | WO2022076685A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3433269B1 (en) * | 2016-03-23 | 2023-09-27 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| WO2018103734A1 (zh) * | 2016-12-09 | 2018-06-14 | 北京中捭生物科技有限公司 | 嵌合抗原受体及其用途和制备方法 |
| US11408005B2 (en) * | 2016-12-12 | 2022-08-09 | Seattle Children's Hospital | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
| WO2018191490A1 (en) * | 2017-04-13 | 2018-10-18 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy |
| MX2020009272A (es) * | 2018-03-06 | 2021-01-08 | Univ Pennsylvania | Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos. |
| CN113840920A (zh) * | 2019-03-14 | 2021-12-24 | 加利福尼亚大学董事会 | 合并的敲入筛选和在内源基因座控制下共表达的异源多肽 |
| SG11202111031RA (en) * | 2019-04-26 | 2021-11-29 | Allogene Therapeutics Inc | Rituximab-resistant chimeric antigen receptors and uses thereof |
-
2021
- 2021-10-07 CA CA3198363A patent/CA3198363A1/en active Pending
- 2021-10-07 JP JP2023521443A patent/JP2023545071A/ja active Pending
- 2021-10-07 WO PCT/US2021/053971 patent/WO2022076685A1/en not_active Ceased
- 2021-10-07 CN CN202180083093.7A patent/CN116917338A/zh active Pending
- 2021-10-07 EP EP21878536.8A patent/EP4229079A4/en active Pending
- 2021-10-07 US US18/030,476 patent/US20230374104A1/en active Pending
- 2021-10-07 AU AU2021358524A patent/AU2021358524A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yan et al. | Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment | |
| Schooten et al. | MAGE-A antigens as targets for cancer immunotherapy | |
| JP7487112B2 (ja) | Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用 | |
| Fesnak et al. | Engineered T cells: the promise and challenges of cancer immunotherapy | |
| Spear et al. | Strategies to genetically engineer T cells for cancer immunotherapy | |
| JP2023085527A5 (https=) | ||
| EP3240805B1 (en) | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 | |
| EP3169703B1 (en) | Chimeric antigen receptor and its use | |
| JP7178568B2 (ja) | がんを治療するための癌胎児性抗原関連細胞接着分子６を標的とするｃａｒ免疫細胞 | |
| JP2024041780A (ja) | 抗ｇｕｃｙ２ｃキメラ抗原受容体の組成物および方法 | |
| JP2022531222A5 (https=) | ||
| US20230210905A1 (en) | T cell-antigen coupler with various construct optimizations | |
| CN110520533A (zh) | 治疗癌症的vegfr-2 car免疫细胞 | |
| CN107835820A (zh) | 识别癌症特异性IL13Rα2的CAR T细胞 | |
| US11332513B2 (en) | Chimeric antigen receptors having GITR intracellular domain as co-stimulatory domain | |
| JP7404279B2 (ja) | 様々な構築物最適化を備えたｔ細胞抗原カプラ | |
| JP7227630B2 (ja) | Ｙ１８２ｔ突然変異を有するｔ細胞－抗原カプラおよびその方法ならびに使用 | |
| CN113717942A (zh) | 一种联合嵌合抗原受体和i型干扰素的免疫治疗方法及其应用 | |
| CN111699201A (zh) | 抗pd-1/抗her2天然抗体结构的异源二聚双特异性抗体及其制备方法 | |
| CN110475857B (zh) | 表达抗-可替宁嵌合抗原受体的天然杀伤细胞 | |
| JP2022519704A5 (https=) | ||
| WO2017179015A1 (en) | Compositions for the treatment of cancer | |
| JP2023545071A5 (https=) | ||
| JP2023549780A5 (https=) | ||
| CN115873801A (zh) | 工程化免疫细胞及其用途 |